Mineralys Therapeutics (MLYS) Income from Continuing Operations (2022 - 2026)

Mineralys Therapeutics has disclosed Income from Continuing Operations across 5 years of filings, most recently posting 39344000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 39344000.0, up 6.79% year-over-year; the trailing twelve-month figure through Mar 2026 was 151787000.0 (up 19.48% YoY), and the FY2025 annual result was 154651000.0, up 13.03% from the prior year.
• Income from Continuing Operations came in at 39344000.0 for Q1 2026 at Mineralys Therapeutics, down from 32235000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 6479000.0 in Q2 2022 to a low of 56332000.0 in Q3 2024.
• The 5-year median for Income from Continuing Operations is 31509000.0 (2024), against an average of 27853764.71.
• Across the five-year window, Income from Continuing Operations plunged 240.62% in 2023 and jumped 34.43% in 2025, its largest moves.
• Mineralys Therapeutics' Income from Continuing Operations stood at 9073000.0 in 2022, then plunged by 168.82% to 24390000.0 in 2023, then tumbled by 100.73% to 48958000.0 in 2024, then jumped by 34.16% to 32235000.0 in 2025, then retreated by 22.05% to 39344000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 39344000.0 (Q1 2026), 32235000.0 (Q4 2025), and 36936000.0 (Q3 2025), per Business Quant data.